JP2025535941A - イブタモレンの圧縮型経口製剤 - Google Patents

イブタモレンの圧縮型経口製剤

Info

Publication number
JP2025535941A
JP2025535941A JP2025523885A JP2025523885A JP2025535941A JP 2025535941 A JP2025535941 A JP 2025535941A JP 2025523885 A JP2025523885 A JP 2025523885A JP 2025523885 A JP2025523885 A JP 2025523885A JP 2025535941 A JP2025535941 A JP 2025535941A
Authority
JP
Japan
Prior art keywords
day
tablet
pharmaceutical solid
pharmaceutical
ibutamoren
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025523885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025535941A5 (https=
Inventor
ビー． パリク，アルパ
シー． マキュー，ジョン
Original Assignee
ルーモス ファーマ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ルーモス ファーマ，インコーポレイテッド filed Critical ルーモス ファーマ，インコーポレイテッド
Publication of JP2025535941A publication Critical patent/JP2025535941A/ja
Priority to JP2025191860A priority Critical patent/JP2026027432A/ja
Publication of JP2025535941A5 publication Critical patent/JP2025535941A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2025523885A 2022-11-03 2022-11-22 イブタモレンの圧縮型経口製剤 Pending JP2025535941A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025191860A JP2026027432A (ja) 2022-11-03 2025-11-12 イブタモレンの圧縮型経口製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263422329P 2022-11-03 2022-11-03
US63/422,329 2022-11-03
PCT/US2022/050700 WO2024096892A1 (en) 2022-11-03 2022-11-22 Compactable oral formulations of ibutamoren

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025191860A Division JP2026027432A (ja) 2022-11-03 2025-11-12 イブタモレンの圧縮型経口製剤

Publications (2)

Publication Number Publication Date
JP2025535941A true JP2025535941A (ja) 2025-10-30
JP2025535941A5 JP2025535941A5 (https=) 2025-11-20

Family

ID=90835855

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2025523885A Pending JP2025535941A (ja) 2022-11-03 2022-11-22 イブタモレンの圧縮型経口製剤
JP2025191860A Pending JP2026027432A (ja) 2022-11-03 2025-11-12 イブタモレンの圧縮型経口製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025191860A Pending JP2026027432A (ja) 2022-11-03 2025-11-12 イブタモレンの圧縮型経口製剤

Country Status (12)

Country Link
US (2) US11969416B1 (https=)
EP (1) EP4611737A1 (https=)
JP (2) JP2025535941A (https=)
KR (1) KR20250107210A (https=)
CN (1) CN120239602A (https=)
AU (1) AU2022485048A1 (https=)
CL (1) CL2025001309A1 (https=)
CO (1) CO2025007025A2 (https=)
GE (1) GEAP202516774A (https=)
IL (1) IL320529A (https=)
MX (1) MX2025005154A (https=)
WO (1) WO2024096892A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250107210A (ko) 2022-11-03 2025-07-11 루모스 파마, 인크. 이부타모렌의 압축형 경구 제형

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021513552A (ja) * 2018-02-14 2021-05-27 ルーモス ファーマ，インコーポレイティド 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US6123964A (en) 1995-10-27 2000-09-26 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
AU7522896A (en) 1995-10-27 1997-05-15 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
BR0113626A (pt) * 2000-08-30 2003-06-17 Pfizer Prod Inc Formulações de liberação sustentada para secretores de hormÈnio do crescimento
US20040005358A1 (en) * 2002-04-23 2004-01-08 Slugg Peter H. Modified-release vasopeptidase inhibitor formulation, combinations and method
EP2001475B1 (en) 2006-03-15 2018-11-14 Michael O. Thorner Methods for treating sarcopenia with a growth hormone secretagogue
FI20080351A0 (fi) 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi
WO2014030204A1 (ja) * 2012-08-20 2014-02-27 大日本住友製薬株式会社 薬物含有中空粒子
CA2889499C (en) 2012-10-24 2019-09-10 Daiichi Sankyo Company, Limited Growth hormone secretagogue receptor agonists for treating amyotrophic lateral sclerosis
BR112015022398B1 (pt) * 2013-03-14 2022-01-11 Redhill Biopharma Ltd Comprimido de ondansetrona e preparação farmacêutica embalada
CA2845443A1 (en) * 2014-03-04 2015-09-04 Pharmascience Inc. Orally disintegrating tablet of nabilone and method of manufacturing
AU2016328969B2 (en) 2015-09-21 2020-10-08 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
KR20250107210A (ko) 2022-11-03 2025-07-11 루모스 파마, 인크. 이부타모렌의 압축형 경구 제형

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021513552A (ja) * 2018-02-14 2021-05-27 ルーモス ファーマ，インコーポレイティド 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物

Also Published As

Publication number Publication date
EP4611737A1 (en) 2025-09-10
GEAP202516774A (en) 2025-06-25
CL2025001309A1 (es) 2025-09-26
WO2024096892A1 (en) 2024-05-10
CO2025007025A2 (es) 2025-07-17
KR20250107210A (ko) 2025-07-11
JP2026027432A (ja) 2026-02-18
CN120239602A (zh) 2025-07-01
US20240245663A1 (en) 2024-07-25
IL320529A (en) 2025-06-01
MX2025005154A (es) 2025-07-01
US11969416B1 (en) 2024-04-30
US20240156793A1 (en) 2024-05-16
AU2022485048A1 (en) 2025-05-22
US12390452B2 (en) 2025-08-19

Similar Documents

Publication Publication Date Title
JP7627302B2 (ja) パルボシクリブの固形剤形
TWI778983B (zh) 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
AU2019280026B2 (en) Galenic formulations of organic compounds
EP2510950B1 (en) Dry-coated orally disintegrating tablet
EP3041476B2 (en) Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
JP2026027432A (ja) イブタモレンの圧縮型経口製剤
WO2014028878A1 (en) Pharmaceutical compositions of memantine
US20060088594A1 (en) Highly compressible controlled delivery compositions of metformin
US20050118256A1 (en) Extended release alpha-2 agonist pharmaceutical dosage forms
US20250332149A1 (en) Piperidine compounds and pharmaceutical compositions
EP4255398B1 (en) Orally-administered preparation containing solifenacin and tamsulosin
US20260041641A1 (en) Novel formulation
RU2773029C2 (ru) Галеновые композиции органических соединений

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251112

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20251112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260306